Alex Nemiroff sold $661k of PRAX
General Counsel and Secretary at Praxis Precision Medicines, Inc.. 8,239 shares at an average of $80.20, traded Nov 14, 2024, filed Nov 15, 2024.
Score components
- +15RoleOfficer
- +20Trade size$661k at market
- +10Share of holdings soldSold 44% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.2%, 3m +26.5%, 6m -48.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-119844, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | MOption exercise Common Stock | +7,583 | $56.94 | $432k | 18,540 | Nov 15, 2024 |
| Nov 14, 2024 | SOpen-market sale Common Stock | -8,239 | $80.20 | $661k | 10,301 | Nov 15, 2024 |
| Nov 14, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -7,583 | $0.00 | $0 | 28,817 | Nov 15, 2024 |
Related signals
Other insiders at Praxis Precision Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | Praxis Precision Medicines, Inc. | Lauren Mastrocola Principal Accounting Officer | $424k 5,188 shares | -48% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.